SecBot SecBot
PRESS-RELEASE ·Filed Mar 16, 2026

NMRA

Neumora Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should prepare for potential volatility following the March 30 earnings release, particularly around pipeline progress, cash runway, and R&D spend. Monitor for updates on clinical trial timelines and funding needs.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.87
T+0 close · Mar 16, 2026 · via day close
Latest settled
−43.55%
T+60 · $1.62
Vs SPY
−54.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 16 $2.87entry
  2. T+1 · 8mo ago −1.39%α −1.67% · $2.83
  3. T+5 · 8mo ago −13.94%α −11.90% · $2.47
  4. T+20 · 7mo ago −29.27%α −33.05% · $2.03
  5. T+60 · 5mo ago −43.55%α −54.04% · $1.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neumora Therapeutics announced it will report its Q4 and full-year 2025 financial results on March 30, 2026, via a live webcast and conference call. No financial data was released in this announcement, it is solely a press release notifying investors of an upcoming earnings event.

Key Facts

  • Neumora Therapeutics will report Q4 and full-year 2025 financial results on March 30, 2026.
  • Event will include a conference call and live webcast at 8:00 a.m. ET.
  • No financial results or business updates were disclosed in this press release.
  • Replay will be available on the company's website for up to 30 days.

Financial Impact

No financial data disclosed, impact to be determined at earnings release.

Risk Factors

  • Biotech earnings can be volatile, especially for clinical-stage companies with no revenue.
  • Potential for dilutive financing if cash runway is short and no partnerships are announced.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3256107

Track record

14 reports on NMRA

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
  3. Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
  5. Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
  6. Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
  7. Aug 14, 202613w ago 8-K Neutral 4/10 No price data
  8. Aug 14, 202613w ago Press Release Neutral 4/10 Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
  9. Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
  10. Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 16, 2026